Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Brokerages

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $5.67.

SGMO has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Sangamo Therapeutics in a report on Wednesday, May 15th. StockNews.com initiated coverage on shares of Sangamo Therapeutics in a report on Friday. They set a “sell” rating for the company.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Wasatch Advisors LP grew its stake in Sangamo Therapeutics by 62.4% in the 1st quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock valued at $13,493,000 after acquiring an additional 7,734,400 shares during the period. Acadian Asset Management LLC grew its stake in Sangamo Therapeutics by 4.0% in the 1st quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock valued at $3,311,000 after acquiring an additional 192,385 shares during the period. Assenagon Asset Management S.A. grew its stake in Sangamo Therapeutics by 14.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock valued at $561,000 after acquiring an additional 129,811 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Sangamo Therapeutics during the 1st quarter worth $331,000. Finally, Golden State Equity Partners boosted its stake in Sangamo Therapeutics by 21.0% during the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 34,960 shares during the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Trading Up 3.7 %

SGMO opened at $0.45 on Friday. Sangamo Therapeutics has a 12-month low of $0.29 and a 12-month high of $1.67. The firm has a market capitalization of $94.38 million, a PE ratio of -0.24 and a beta of 1.24. The firm has a 50 day moving average of $0.50 and a two-hundred day moving average of $0.61.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). The firm had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $8.51 million. Sangamo Therapeutics had a negative net margin of 1,749.06% and a negative return on equity of 182.55%. During the same period last year, the firm earned $0.12 earnings per share. As a group, analysts predict that Sangamo Therapeutics will post -0.55 EPS for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.